Conducting a Policy Analysis Study on the Medicaid Funding Freeze

People searching for a medicaid funding freeze policy analysis study usually do not need another opinion piece in a policy debate. They need the method: what counts as a policy analysis, how the question gets framed, which evidence is admissible, and how a recommendation is defended without pretending the answer was fixed in advance. Bowen and Zwi treat policy analysis as a research method with traditional, mainstream, and interpretive orientations, which matters because each one makes different assumptions about evidence, objectivity, and how much uncertainty the analyst should admit [1].

Policy analysis, not advocacy

The cleanest first distinction is between policy analysis, advocacy, and policy reporting. Reporting tells the reader what happened. Advocacy starts with a preferred outcome and gathers support for it. Policy analysis compares alternatives against criteria that are stated up front and then revises the recommendation only if the evidence or the criteria change. That is why two honest analysts can look at the same Medicaid financing shock and still land on different recommendations: they may be using different assumptions, different evidence thresholds, or different decision rules [1].

Frameworks that organize the work

For students, Bardach's Eightfold Path is the most teachable sequence because it turns a vague memo assignment into a repeatable workflow: define the problem, assemble evidence, construct alternatives, select criteria, project outcomes, confront trade-offs, decide, and tell the story [2]. CDC POLARIS is a shorter public-health lens that reaches the same basic task from a different angle, with more explicit attention to stakeholder involvement and feasibility in implementation [3]. Bardach gives the spine of the memo; POLARIS reminds the analyst that a technically neat option can still fail if the people who must carry it out cannot use it.

• Define the problem.
• Assemble evidence.
• Construct alternatives.
• Select criteria.
• Project outcomes.
• Confront trade-offs.
• Decide.
• Tell the story.

Using the Medicaid case

The 2025 reconciliation law makes the Medicaid funding freeze a serious case for method, not just politics. KFF reports that the law reduced projected federal Medicaid spending by $911 billion over 10 years, that the package includes a provider tax prohibition effective July 2025, and that the resulting financing changes could leave 7.5 million people newly uninsured by 2034 [4]. CBPP's framing helps narrow the policy menu to three core designs: current-law FMAP, a per-capita cap, and a block grant [5].

That is enough to define the real question. The analyst is not being asked whether Medicaid is good in the abstract or whether federal spending should be lower in the abstract. The question is which financing structure best satisfies the stated criteria under the new constraints. If budget stability is the main criterion, capped funding can look attractive because it limits federal exposure. If coverage loss is weighted more heavily, current-law FMAP may look better because it preserves the existing federal match. If implementation feasibility is decisive, the choice may turn on whether states can absorb the administrative change without breaking the program's day-to-day operations.

• Current-law FMAP keeps the existing federal-state matching structure in place, which preserves the current financing logic but does not answer the pressure on federal spending.
• A per-capita cap limits federal growth per enrollee, which improves predictability for the federal budget while shifting more risk to states if enrollment or medical costs rise.
• A block grant fixes federal funding at a set amount; CBPP's analysis of that design projects a $225 billion state fiscal gap over 10 years [5].

The evidence step is where a memo stops sounding like a headline recap. SHVS provides a practical toolkit for pulling state-level impacts into view, which is useful when the analyst needs enrollment, budget, and program data rather than national talking points [6]. The Medicaid policy-data literature also shows why eligibility and programmatic changes have to be measured at the rule and enrollment level, not only through aggregate spending totals [7]. In other words, the analyst has to know who is affected, how many people are at risk, which state rules change, and where the operational burden lands.

Where POLARIS helps

CDC POLARIS is useful when the question sits in public health rather than only in budget law. Its stakeholder and feasibility emphasis pushes the analyst to ask who must implement the change, who bears the disruption, and whether the proposal survives contact with state agencies, providers, and beneficiaries [3]. That does not replace Bardach's sequence. It sharpens it by forcing the memo to show whether the recommendation is administratively real or merely elegant on paper.

What a strong memo makes visible

A strong policy analysis memo leaves the reader able to audit the work. The problem statement is explicit. The evidence base is named. The alternatives are concrete. The criteria are visible before the verdict arrives. The trade-offs are not buried. That is the main discipline behind a credible policy analysis study: not pretending to be neutral in every sense, but making the assumptions, thresholds, and uncertainties clear enough that another reader can see why the recommendation follows. Once those pieces are visible, the memo is doing analysis instead of wearing the costume of analysis.

References

1. A guide to policy analysis as a research method — Health Promotion International, 2018
2. A Practical Guide for Policy Analysis: The Eightfold Path to More Effective Problem Solving — Sage Publishing
3. Policy Analysis | POLARIS | CDC — CDC
4. Medicaid: What to Watch in 2026 — KFF
5. Medicaid Block Grant Would Slash Federal Funding, Shift Costs to States, and Leave Millions More Uninsured — CBPP
6. Analyzing the Impact of Potential Medicaid Cuts: A Toolkit for States — SHVS
7. Medicaid policy data for evaluating eligibility and programmatic changes — PubMed Central